DexCom Launches GenAI Platform for Glucose Biosensing, Leveraging Google Cloud

DexCom, a glucose biosensing technology company, unveiled its proprietary Generative AI (GenAI) platform on Tuesday, December 17, becoming the first CGM manufacturer to integrate advanced AI into glucose biosensing technology. The new Dexcom GenAI platform leverages Google Cloud’s Vertex AI and Gemini models to analyse individual health data, offering personalised insights that link lifestyle choices to glucose levels. This aims to help users make informed decisions to improve metabolic health, the company said.

• Make Telecom Talk My Trusted Source
• 
• 

Also Read: Nvidia and Partners Develop AI Model to Predict Future Glucose Levels in Individuals

Stelo GenAI Platform

Stelo, the first over-the-counter glucose biosensor FDA-cleared in the US, is the first Dexcom product to use GenAI technology to produce weekly insights. DexCom said the enhancement of Stelo’s Weekly Insights feature began rolling out to users this week. GenAI-powered messaging enhances Stelo’s existing Weekly Insights by providing users with more personalised tips, recommendations, and education related to diet, exercise, and sleep within the Stelo app, delivering actionable health recommendations.

GenAI-Powered Health Advancements

“The launch of our GenAI platform reinforces our long-standing reputation as the glucose biosensing leader and opens the door for future advancements across our product portfolio,” said Jake Leach, executive vice president and chief operating officer at Dexcom. “Innovation is at the core of what we do. We look forward to introducing additional GenAI-powered features over the next year to help users contextualise their health information and make proactive, informed lifestyle decisions.”

Also Read: Microsoft Announces New AI Models and Solutions for Healthcare